# Illumina Moat

Status: published. Policy: company-analysis-1.

Illumina has a commercially adopted proprietary technology franchise, supported by patents, continued consumables demand and NovaSeq X adoption. The passages do not establish how effectively its intellectual property excludes alternatives or how costly switching is for customers. Actual competitive pricing pressure and longer sales cycles constrain pricing power; tariff-related pricing actions show some flexibility, but not sustained price realization. The evidence supports an operating franchise without establishing a durable economic moat.

## intangible_assets

Patents covering sequencing technologies, instruments, assays and software provide a current proprietary foundation. NovaSeq X adoption demonstrates commercialization, but the passages do not establish that these rights create a durable economic advantage over alternatives.

Durability: Patent expirations range from 2025 through 2049, but the economic importance of individual patents, their enforceability and competitors' ability to design around them are undisclosed. Continued innovation is necessary; patent terms and accounting useful lives do not establish moat duration.

Risks: Realized competitive pricing pressure and lengthened sales cycles indicate erosion. Alternative technologies address applications where Illumina is less suited. Third-party licensing and the historical settlement payment also demonstrate that intellectual property can impose costs on Illumina.

Invalidation: A defensible proprietary-advantage thesis would be invalidated by evidence that alternatives can routinely substitute for its core workflows without material performance or conversion penalties, or that expiry, invalidation or design-arounds of economically important patents cause sustained customer losses and pricing concessions. The supplied passages do not establish those outcomes.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/1110803/000111080326000024/ilmn-20251228.htm](https://www.sec.gov/Archives/edgar/data/1110803/000111080326000024/ilmn-20251228.htm) · 2026-02-12
- [https://www.sec.gov/Archives/edgar/data/1110803/000111080326000160/ilmn-20260628.htm](https://www.sec.gov/Archives/edgar/data/1110803/000111080326000160/ilmn-20260628.htm) · 2026-07-31
- [https://www.sec.gov/Archives/edgar/data/1110803/000119312526149669/d13789ddef14a.htm](https://www.sec.gov/Archives/edgar/data/1110803/000119312526149669/d13789ddef14a.htm) · 2026-04-09
- [https://www.sec.gov/Archives/edgar/data/1110803/000111080325000019/ilmn-20241229.htm](https://www.sec.gov/Archives/edgar/data/1110803/000111080325000019/ilmn-20241229.htm) · 2025-02-12
- [https://www.sec.gov/Archives/edgar/data/1110803/000111080324000010/ilmn-20231231.htm](https://www.sec.gov/Archives/edgar/data/1110803/000111080324000010/ilmn-20231231.htm) · 2024-02-16
- [https://www.sec.gov/Archives/edgar/data/1110803/000111080326000092/ilmn-20260329.htm](https://www.sec.gov/Archives/edgar/data/1110803/000111080326000092/ilmn-20260329.htm) · 2026-05-04

[JSON](https://beanvest.com/stock/ilmn/moat.json)